186 related articles for article (PubMed ID: 20400230)
41. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration.
Zhong Z; Deane R; Ali Z; Parisi M; Shapovalov Y; O'Banion MK; Stojanovic K; Sagare A; Boillee S; Cleveland DW; Zlokovic BV
Nat Neurosci; 2008 Apr; 11(4):420-2. PubMed ID: 18344992
[TBL] [Abstract][Full Text] [Related]
42. No evidence of microbleeds in ALS patients at 7 Tesla MRI.
Verstraete E; Biessels GJ; van Den Heuvel MP; Visser F; Luijten PR; van Den Berg LH
Amyotroph Lateral Scler; 2010 Dec; 11(6):555-7. PubMed ID: 20812888
[TBL] [Abstract][Full Text] [Related]
43. Altered blood-brain barrier and blood-spinal cord barrier dynamics in amyotrophic lateral sclerosis: Impact on medication efficacy and safety.
Pan Y; Nicolazzo JA
Br J Pharmacol; 2022 Jun; 179(11):2577-2588. PubMed ID: 35048358
[TBL] [Abstract][Full Text] [Related]
44. Chronic cerebrospinal venous insufficiency and multiple sclerosis: history and background.
Dake MD
Tech Vasc Interv Radiol; 2012 Jun; 15(2):94-100. PubMed ID: 22640498
[TBL] [Abstract][Full Text] [Related]
45. [Etiological studies of ALS (amyotrophic lateral sclerosis) and intrinsic serum factors].
Sobue I; Sugimura K
Nihon Rinsho; 1977 Nov; 35(11):4030-6. PubMed ID: 340731
[No Abstract] [Full Text] [Related]
46. Alterations in the blood-spinal cord barrier in TDP-43 conditional knockout mice.
Sasaki S; Iguchi Y; Katsuno M; Sobue G
Neurosci Lett; 2015 Jun; 598():1-5. PubMed ID: 25957558
[TBL] [Abstract][Full Text] [Related]
47. Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability.
Winkler EA; Sengillo JD; Bell RD; Wang J; Zlokovic BV
J Cereb Blood Flow Metab; 2012 Oct; 32(10):1841-52. PubMed ID: 22850407
[TBL] [Abstract][Full Text] [Related]
48. Inflammation and dephosphorylation of the tight junction protein occludin in an experimental model of multiple sclerosis.
Morgan L; Shah B; Rivers LE; Barden L; Groom AJ; Chung R; Higazi D; Desmond H; Smith T; Staddon JM
Neuroscience; 2007 Jul; 147(3):664-73. PubMed ID: 17560040
[TBL] [Abstract][Full Text] [Related]
49. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis.
Plumb J; McQuaid S; Mirakhur M; Kirk J
Brain Pathol; 2002 Apr; 12(2):154-69. PubMed ID: 11958369
[TBL] [Abstract][Full Text] [Related]
50. Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study.
Deeb O; Nabulsi M
Curr Top Med Chem; 2020; 20(26):2391-2403. PubMed ID: 32972341
[TBL] [Abstract][Full Text] [Related]
51. [Amyotrophic lateral sclerosis--causative role of trace elements].
Yase Y
Nihon Rinsho; 1996 Jan; 54(1):123-8. PubMed ID: 8587178
[TBL] [Abstract][Full Text] [Related]
52. Reduction of circulating endothelial cells in peripheral blood of ALS patients.
Garbuzova-Davis S; Woods RL; Louis MK; Zesiewicz TA; Kuzmin-Nichols N; Sullivan KL; Miller AM; Hernandez-Ontiveros DG; Sanberg PR
PLoS One; 2010 May; 5(5):e10614. PubMed ID: 20485543
[TBL] [Abstract][Full Text] [Related]
53. Breached Barriers: A Scoping Review of Blood-Central Nervous System Barrier Pathology in Amyotrophic Lateral Sclerosis.
Mirian A; Moszczynski A; Soleimani S; Aubert I; Zinman L; Abrahao A
Front Cell Neurosci; 2022; 16():851563. PubMed ID: 35431812
[TBL] [Abstract][Full Text] [Related]
54. Mercury in the spinal cord after inhalation of mercury.
Roos PM; Dencker L
Basic Clin Pharmacol Toxicol; 2012 Aug; 111(2):126-32. PubMed ID: 22364490
[TBL] [Abstract][Full Text] [Related]
55. Blood-CNS Barrier Impairment in ALS patients versus an animal model.
Garbuzova-Davis S; Sanberg PR
Front Cell Neurosci; 2014; 8():21. PubMed ID: 24550780
[TBL] [Abstract][Full Text] [Related]
56. Nanofiber mat spinal cord dressing-released glutamate impairs blood-spinal cord barrier.
Sulejczak D; Taraszewska A; Chrapusta SJ; Dziewulska D; Nakielski P; Rafałowska J
Folia Neuropathol; 2016; 54(4):392-404. PubMed ID: 28139821
[TBL] [Abstract][Full Text] [Related]
57. Blood brain barrier compromise with endothelial inflammation may lead to autoimmune loss of myelin during multiple sclerosis.
Simka M
Curr Neurovasc Res; 2009 May; 6(2):132-9. PubMed ID: 19442163
[TBL] [Abstract][Full Text] [Related]
58. Amyotrophic lateral sclerosis: what role does environment play?
Ahmed A; Wicklund MP
Neurol Clin; 2011 Aug; 29(3):689-711. PubMed ID: 21803219
[TBL] [Abstract][Full Text] [Related]
59. ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis.
Jablonski M; Miller DS; Pasinelli P; Trotti D
Brain Res; 2015 May; 1607():1-14. PubMed ID: 25175835
[TBL] [Abstract][Full Text] [Related]
60. Amyotrophic lateral sclerosis: The complement and inflammatory hypothesis.
Kjældgaard AL; Pilely K; Olsen KS; Pedersen SW; Lauritsen AØ; Møller K; Garred P
Mol Immunol; 2018 Oct; 102():14-25. PubMed ID: 29933890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
